Quality key factors
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
0.00%
EBIT to Interest (avg)
-17.28
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
34.77%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.01
EV to EBIT
-24.60
EV to EBITDA
-25.77
EV to Capital Employed
30.14
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-122.50%
ROE (Latest)
-16.31%
1What is working for the Company
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Hanx Biopharmaceuticals (Wuhan) Co. Ltd.
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Footer loading






